In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a price target of $5.00. The company’s shares opened today at $0.44.
According to TipRanks, Ramakanth is an analyst with an average return of -23.9% and a 21.60% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, MiMedx Group, and Ocugen.
Currently, the analyst consensus on Ocugen is a Moderate Buy with an average price target of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.36 and a one-year low of $0.40. Currently, Ocugen has an average volume of 5.1M.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Read More on OCGN:
- Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
- Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
- Biotech Alert: Searches spiking for these stocks today
- Ocugen Provides Business Update with Second Quarter 2023 Financial Results
- Ocugen reports Q2 EPS (10c), consensus (7c)
